Literature DB >> 26269396

EDA-ID and IP, two faces of the same coin: how the same IKBKG/NEMO mutation affecting the NF-κB pathway can cause immunodeficiency and/or inflammation.

Francesca Fusco1, Alessandra Pescatore1, Matilde Immacolata Conte1, Peppino Mirabelli2, Mariateresa Paciolla1,3, Elio Esposito1, Maria Brigida Lioi3, Matilde Valeria Ursini1,2.   

Abstract

Anhidrotic Ectodermal Dysplasia with ImmunoDeficiency (EDA-ID, OMIM 300291) and Incontinentia Pigmenti (IP, OMIM 308300) are two rare diseases, caused by mutations of the IKBKG/NEMO gene. The protein NEMO/IKKγ is essential for the NF-κB activation pathway, involved in a variety of physiological and cellular processes, such as immunity, inflammation, cell proliferation, and survival. A wide spectrum of IKBKG/NEMO mutations have been identified so far, and, on the basis of their effect on NF-κB activation, they are considered hypomorphic or amorphic (loss of function) mutations. IKBKG/NEMO hypomorphic mutations, reducing but not abolishing NF-κB activation, have been identified in EDA-ID and IP patients. Instead, the amorphic mutations, abolishing NF-κB activation by complete IKBKG/NEMO gene silencing, cause only IP. Here, we present an overview of IKBKG/NEMO mutations in EDA-ID and IP patients and describe similarities and differences between the clinical/immunophenotypic and genetic aspects, highlighting any T and B lymphocyte defect, and paying particular attention to the cellular and molecular defects that underlie the pathogenesis of both diseases.

Entities:  

Keywords:  IKBKG/NEMO mutations; NF-κB; immunodeficiency; inflammation; mutation sequence analysis

Mesh:

Substances:

Year:  2015        PMID: 26269396     DOI: 10.3109/08830185.2015.1055331

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  28 in total

1.  The Incontinentia Pigmenti Genetic Biobank: study design and cohort profile to facilitate research into a rare disease worldwide.

Authors:  Francesca Fusco; Valeria Valente; Dario Fergola; Alessandra Pescatore; Maria Brigida Lioi; Matilde Valeria Ursini
Journal:  Eur J Hum Genet       Date:  2019-06-23       Impact factor: 4.246

2.  Clinical utility gene card: for incontinentia pigmenti.

Authors:  Francesca Fusco; Alessandra Pescatore; Julie Steffann; Jean-Paul Bonnefont; Judite De Oliveira; Maria Brigida Lioi; Matilde Valeria Ursini
Journal:  Eur J Hum Genet       Date:  2019-07-09       Impact factor: 4.246

3.  Rescue of recurrent deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency.

Authors:  Bertrand Boisson; Yoshitaka Honda; Masahiko Ajiro; Jacinta Bustamante; Matthieu Bendavid; Andrew R Gennery; Yuri Kawasaki; Jose Ichishima; Mitsujiro Osawa; Hiroshi Nihira; Takeshi Shiba; Takayuki Tanaka; Maya Chrabieh; Benedetta Bigio; Hong Hur; Yuval Itan; Yupu Liang; Satoshi Okada; Kazushi Izawa; Ryuta Nishikomori; Osamu Ohara; Toshio Heike; Laurent Abel; Anne Puel; Megumu K Saito; Jean-Laurent Casanova; Masatoshi Hagiwara; Takahiro Yasumi
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

Review 4.  Human IκBα Gain of Function: a Severe and Syndromic Immunodeficiency.

Authors:  Bertrand Boisson; Anne Puel; Capucine Picard; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2017-06-09       Impact factor: 8.317

5.  Store-operated Ca2+ entry regulates Ca2+-activated chloride channels and eccrine sweat gland function.

Authors:  Axel R Concepcion; Martin Vaeth; Larry E Wagner; Miriam Eckstein; Lee Hecht; Jun Yang; David Crottes; Maximilian Seidl; Hyosup P Shin; Carl Weidinger; Scott Cameron; Stuart E Turvey; Thomas Issekutz; Isabelle Meyts; Rodrigo S Lacruz; Mario Cuk; David I Yule; Stefan Feske
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

Review 6.  Regulation of epithelial ion transport in exocrine glands by store-operated Ca2+ entry.

Authors:  Axel R Concepcion; Stefan Feske
Journal:  Cell Calcium       Date:  2016-12-21       Impact factor: 6.817

7.  Structurally plastic NEMO and oligomerization prone IKK2 subunits define the behavior of human IKK2:NEMO complexes in solution.

Authors:  Myung Soo Ko; Tapan Biswas; Maria Carmen Mulero; Andrey A Bobkov; Gourisankar Ghosh; Tom Huxford
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-08-25       Impact factor: 3.036

8.  Functional Evaluation of an IKBKG Variant Suspected to Cause Immunodeficiency Without Ectodermal Dysplasia.

Authors:  Glynis Frans; Jutte van der Werff Ten Bosch; Leen Moens; Rik Gijsbers; Majid Changi-Ashtiani; Hassan Rokni-Zadeh; Mohammad Shahrooei; Greet Wuyts; Isabelle Meyts; Xavier Bossuyt
Journal:  J Clin Immunol       Date:  2017-10-10       Impact factor: 8.317

9.  T Cell Impairment Is Predictive for a Severe Clinical Course in NEMO Deficiency.

Authors:  Stephanie Heller; Uwe Kölsch; Thomas Magg; Renate Krüger; Andrea Scheuern; Holm Schneider; Anna Eichinger; Volker Wahn; Nadine Unterwalder; Myriam Lorenz; Klaus Schwarz; Christian Meisel; Ansgar Schulz; Fabian Hauck; Horst von Bernuth
Journal:  J Clin Immunol       Date:  2020-01-21       Impact factor: 8.317

10.  Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations.

Authors:  Charline Miot; Kohsuke Imai; Chihaya Imai; Anthony J Mancini; Zeynep Yesim Kucuk; Tokomki Kawai; Ryuta Nishikomori; Etsuro Ito; Isabelle Pellier; Sophie Dupuis Girod; Jeremie Rosain; Shinya Sasaki; Shanmuganathan Chandrakasan; Jana Pachlopnik Schmid; Tsubasa Okano; Estelle Colin; Alberto Olaya-Vargas; Marco Yamazaki-Nakashimada; Waseem Qasim; Sara Espinosa Padilla; Andrea Jones; Alfons Krol; Nyree Cole; Stephen Jolles; Jack Bleesing; Thomas Vraetz; Andrew R Gennery; Mario Abinun; Tayfun Güngör; Beatriz Costa-Carvalho; Antonio Condino-Neto; Paul Veys; Steven M Holland; Gulbu Uzel; Despina Moshous; Benedicte Neven; Stéphane Blanche; Stephan Ehl; Rainer Döffinger; Smita Y Patel; Anne Puel; Jacinta Bustamante; Erwin W Gelfand; Jean-Laurent Casanova; Jordan S Orange; Capucine Picard
Journal:  Blood       Date:  2017-07-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.